Last updated on December 2018

Home Therapy With Replagal in Fabry Disease

Brief description of study

The purpose of this study is to proof increasing patient satisfaction and preservation of quality of life in patients with Morbus Fabry disease receiving their Enzyme Replacement Therapy with Replagal (Agalsidase alfa) at home compared to receiving the infusions at the clinic or at doctor's practice.

Clinical Study Identifier: NCT01355146

Contact Investigators or Research Sites near you

Start Over

Volkmar Lufft, MD

Nephrologisches Zentrum Rendsburg
Rendsburg, Germany

Recruitment Status: Closed

Brief Description Eligibility Contact Research Team

Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.